THE BINDING SITE

23 recall(s) on record — most severe on record: Class II.

Devices registered here (1)

• Complement C1 Inhibitor (Inactivator), Antigen, Antiserum, Control
  Product code DBA · Class II · Immunology · 21 CFR 866.5250

Recalls & enforcement

• Class IIOngoing2026-04-16
  It was reported that plates 2 and 3 were marked as passed , although it appeared that QC had not been performed on these plates, despite samples being measured. The potential clinical hazards include false or missed detection of M-protein (false positive); and falsely elevated o
• Class IITerminated2021-10-15
  Due to calibration curves producing a higher activity than routinely expected and that there may be a decrease in separation between calibrator point 5 and calibrator point 6, which can be exacerbated with calibrator 6 activity reaches the optical ceiling of the SPA+ analyzer.
• Class IITerminated2021-05-20
  The high and low level "Quality Controls" demonstrate a positive bias of approximately 10% compared to assigned values.
• Class IITerminated2020-11-18
  Due to customer complaints of positive bias impacting quality control. The high and low level controls are demonstrating a positive bias compared to assigned values.
• Class IITerminated2020-04-09
  A software issue that may affect the analyzer's result accuracy.
• Class IITerminated2019-11-06
  It has been identified that the rheumatoid factor (RF) calibrator values over recover in comparison to the reference material RF serum. This could result in reporting falsely abnormal results which may lead to unnecessary additional serological testing.
• Class IITerminated2019-10-07
  Assigned Rheumatoid Factor (RF) calibrator value for calibrator component included in kit used to aid in the diagnosis of rheumatoid arthritis over recovers by 7% in comparison to the reference material RF serum. This could result in reporting abnormal (false positive) results,
• Class IITerminated2019-07-29
  There is a potential that users may experience difficulty validating the calibration of the kit. This is indicated by kit control values reporting outside the specified ranges. This could result in potential false patient results which could cause a delay until repeat testing is
• Class IITerminated2019-04-25
  A reagent in C reactive protein kits is not performing to specification and samples with known concentrations less-than-or-equal to 10 mg/L may be affected
• Class IITerminated2019-02-19
  Deterioration of C-reactive protein (CRP) reagent in Optilite C-Reactive Protein Kits
• Class IITerminated2018-11-06
  Firm is offering advice to customers experiencing challenges when validating the calibration curve of the IgM kits. This is indicated by kit control values reporting outside the specified ranges.
• Class IITerminated2018-08-12
  A deterioration of performance was identified with influenza type B Enzyme Immunoassay Kits with findings of a positive bias with kit controls. Patient sample results may be affected with falsely elevated results incorrectly indicating a protective level of anti-Hib antibody in t
• Class IITerminated2018-07-25
  After running the calibration curve, the recovery of the IgM kit control results decrease demonstrating a reduction in accuracy within the same day; control results may be out of range one day after running the assay calibration curve. Samples have been shown to be similarly affe
• Class IITerminated2018-03-09
  The product is not meeting the antigen excess protection claim of up to 760mg/L, as stated in the Instructions for Use.
• Class IITerminated2018-01-04
  The low and high controls for the product are returning results above the assigned values.
• Class IITerminated2017-08-23
  The high control for the kit is recovering low and may be out of range for assigned values.
• Class IIITerminated2016-12-23
  A change to the lower end of the measuring range and product insert did not reflect the change.The measuring range provided in instrument parameters is correct but contradicts the information provided in the product insert
• Class IITerminated2016-10-28
  A change in the calibration curve causing an increase in false prozone flags.
• Class IITerminated2016-07-05
  Batch numbers listed are reporting Lambda Free Light Chain results >114mg/L that are on average 33% lower than other Optilite Lambda Freelite batches. Therefore users moving to this batch will see results >114mg/L giving lower results and conversely when switching to the ne
• Class IITerminated2015-05-13
  Potential risk of the Optilite lid/cover falling suddenly and causing injury when not placed in the fully open position.
• Class IITerminated2014-09-11
  Customer complaints identified that samples containing extremely high IgG4 levels exhibit antigen excess and will yield spuriously low IgG4 results.
• Class IITerminated2012-11-28
  Calibration curve activity has increased over time in the kit lots listed.
• Class IITerminated2012-10-09
  If a control ring is marked after reading, the software will not flag results that are out of the specified QC range.

Related

• All facilities operated by THE BINDING SITE
• The Binding Site Group Ltd. (GB)

Source: U.S. FDA via openFDA (device registration & enforcement). Data as of 2026-08-13. Verify this facility record at FDA →